Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3818805 | 0.96 | ALDH1A1 (0.60) | ALDH1A1PTGS1KMT2AMEN1POLB | |
| SCHEMBL3818808 | 0.96 | ALDH1A1 (0.60) | ALDH1A1PTGS1KMT2AMEN1POLB | |
| SCHEMBL2601974 | 0.92 | INSR (0.54) | ALDH1A1PTGS1KMT2AMEN1POLB | |
| SCHEMBL6171639 | 0.91 | ALDH1A1 (0.78) | ALDH1A1KMT2AMEN1POLBTSHR | |
| SCHEMBL5681740 | 0.85 | ALDH1A1 (0.85) | ALDH1A1KMT2AMEN1POLBTSHR | |
| SCHEMBL179008 | 0.83 | INSR (0.54) | ALDH1A1PTGS1KMT2AMEN1POLB | |
| SCHEMBL21345576 | 0.82 | PTGS1 (0.58) | ALDH1A1PTGS1KMT2AMEN1POLB | |
| SCHEMBL23417795 | 0.82 | CYP4F2 (0.51) | ALDH1A1KMT2A | |
| SCHEMBL14564764 | 0.81 | TRPV1 (0.69) | ALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL5707095 | 0.81 | MTNR1A (0.69) | ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964642-B2 | Antiinflammatory agents, analgesics; 2-halo-4-hydroxy-5-methoxyphenyl-functional urea or thiourea compounds such as 1-(p-trifluoromethylbenzyl)-3-(2-iodo-4-hydroxy-5-methoxybenzyl)thiourea | PHARMESTE S.R.L. (IT) | 2011-06-21 | — | — | US | disclosed |
| US-7964642-B2 | Antiinflammatory agents, analgesics; 2-halo-4-hydroxy-5-methoxyphenyl-functional urea or thiourea compounds such as 1-(p-trifluoromethylbenzyl)-3-(2-iodo-4-hydroxy-5-methoxybenzyl)thiourea | PHARMESTE S.R.L. (IT) | 2011-06-21 | — | — | US | disclosed |
| US-7964642-B2 | Antiinflammatory agents, analgesics; 2-halo-4-hydroxy-5-methoxyphenyl-functional urea or thiourea compounds such as 1-(p-trifluoromethylbenzyl)-3-(2-iodo-4-hydroxy-5-methoxybenzyl)thiourea | PHARMESTE S.R.L. (IT) | 2011-06-21 | — | — | US | disclosed |
| EP-2094653-B1 | O-SUBSTITUTED-DIBENZYL UREA-DERIVATIVES AS TRPV1 RECEPTOR ANTAGONISTS | PHARMESTE SRL (IT) | 2010-09-01 | — | — | EP | disclosed |
| US-7750049-B2 | O-substituted-dibenzyl urea-derivatives as TRPV1 receptor antagonists | PHARMESTE S.R.L. (IT) | 2010-07-06 | — | — | US | disclosed |
| US-7750049-B2 | O-substituted-dibenzyl urea-derivatives as TRPV1 receptor antagonists | PHARMESTE S.R.L. (IT) | 2010-07-06 | — | — | US | disclosed |
| US-7750049-B2 | O-substituted-dibenzyl urea-derivatives as TRPV1 receptor antagonists | PHARMESTE S.R.L. (IT) | 2010-07-06 | — | — | US | disclosed |
| US-20100105740-A1 | O-SUBSTITUTED-DIBENZYL UREA-DERIVATIVES AS TRPV1 RECEPTOR ANTAGONISTS | SERENTRIX, LLC | 2010-04-29 | — | — | US | disclosed |
| US-20100105740-A1 | O-SUBSTITUTED-DIBENZYL UREA-DERIVATIVES AS TRPV1 RECEPTOR ANTAGONISTS | SERENTRIX, LLC | 2010-04-29 | — | — | US | disclosed |
| US-20100105740-A1 | O-SUBSTITUTED-DIBENZYL UREA-DERIVATIVES AS TRPV1 RECEPTOR ANTAGONISTS | SERENTRIX, LLC | 2010-04-29 | — | — | US | disclosed |
| EP-1939173-A1 | O-substituted-dibenzyl urea- or thiourea- derivatives as trpv1 receptor antagonists | Pharmeste S.r.l. (IT) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939173-A1 | O-substituted-dibenzyl urea- or thiourea- derivatives as trpv1 receptor antagonists | Pharmeste S.r.l. (IT) | 2008-07-02 | — | — | EP | disclosed |
| US-20080085936-A1 | Antiinflammatory agents, analgesics; 2-halo-4-hydroxy-5-methoxyphenyl-functional urea or thiourea compounds such as 1-(p-trifluoromethylbenzyl)-3-(2-iodo-4-hydroxy-5-methoxybenzyl)thiourea | PHARMESTE S.R.L. (IT) | 2008-04-10 | — | — | US | disclosed |
| US-20080085936-A1 | Antiinflammatory agents, analgesics; 2-halo-4-hydroxy-5-methoxyphenyl-functional urea or thiourea compounds such as 1-(p-trifluoromethylbenzyl)-3-(2-iodo-4-hydroxy-5-methoxybenzyl)thiourea | PHARMESTE S.R.L. (IT) | 2008-04-10 | — | — | US | disclosed |
| US-20080085936-A1 | Antiinflammatory agents, analgesics; 2-halo-4-hydroxy-5-methoxyphenyl-functional urea or thiourea compounds such as 1-(p-trifluoromethylbenzyl)-3-(2-iodo-4-hydroxy-5-methoxybenzyl)thiourea | PHARMESTE S.R.L. (IT) | 2008-04-10 | — | — | US | disclosed |
| EP-1805138-B1 | SULFONAMIDO COMPOUNDS THAT ANTAGONISE THE VANILLOID TRPV1 RECEPTOR | PHARMESTE SRL (IT) | 2008-03-19 | — | — | EP | disclosed |
| EP-1805138-A1 | SULFONAMIDO COMPOUNDS THAT ANTAGONISE THE VANILLOID TRPV1 RECEPTOR | Pharmeste S.r.l. (IT) | 2007-07-11 | — | — | EP | disclosed |
| EP-1758851-A1 | VANILLOID TRPV1 RECEPTOR ANTAGONISTS | Pharmeste S.r.l. (IT) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006045498-A1 | SULFONAMIDO COMPOUNDS THAT ANTAGONISE THE VANILLOID TRPV1 RECEPTOR | PHARMESTE S.R.L. (IT) | 2006-05-04 | — | — | WO | disclosed |
| WO-2005123666-A1 | VANILLOID TRPV1 RECEPTOR ANTAGONISTS | PHARMESTE S.R.L. (IT) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085936-A1 | Antiinflammatory agents, analgesics; 2-halo-4-hydroxy-5-methoxyphenyl-functional urea or thiourea compounds such as 1-(p-trifluoromethylbenzyl)-3-(2-iodo-4-hydroxy-5-methoxybenzyl)thiourea | SIGMAR1, PTGS1, TPMT | ALDH1A1 339/4885PTGS1 2/4885KMT2A 3805/4885 |
| US-20100105740-A1 | O-SUBSTITUTED-DIBENZYL UREA-DERIVATIVES AS TRPV1 RECEPTOR ANTAGONISTS | TRPV1, TRPV5, TRPA1 | ALDH1A1 2576/4885PTGS1 276/4885KMT2A 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.